Add One More to the List of Revised BE Guidance on Extended-Release Products
FDA issued a revised bioequivalence recommendation for Lamotrigine ER Tablets calling on the firms to perform fasting and fed bioequivalence studies on the 200 mg tablet and a fasting study on the 50 mg. Neither of these products are the highest or lowest strength in the product strength range of 25 mg to 300 mg […]